Cargando…

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer

In the latest years, some drugs have been approved by European Medicines Agency (EMA) and/or the US Food and Drug Administration (FDA) for the treatment of patients with advanced non-small cell lung cancer (NSCLC), particularly for the treatment of those who have no targeted gene mutations or who ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hongge, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699593/ https://www.ncbi.nlm.nih.gov/pubmed/31616186 http://dx.doi.org/10.2147/CMAR.S212238

Ejemplares similares

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Prognostic impact of maximum standardized uptake value on (18)F‐FDG PET/CT imaging of the primary lung lesion on survival in advanced non‐small cell lung cancer: A retrospective study
por: Qiu, Xiaoling, et al.
Publicado: (2021)

Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
por: Adhoute, Xavier, et al.
Publicado: (2022)

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Tian, Wentao, et al.
Publicado: (2020)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

Newly developed anti-angiogenic therapy in non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2017)

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review
por: Ning, Xiangu, et al.
Publicado: (2021)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
por: Goedegebuure, Ruben S. A., et al.
Publicado: (2019)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer
por: Liu, Ziwei, et al.
Publicado: (2020)

Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer
por: Gu, Xinpei, et al.
Publicado: (2022)

Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer
por: Liang, Hongge, et al.
Publicado: (2022)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas
por: Passalidou, E, et al.
Publicado: (2002)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
por: Lee, Tai-Huang, et al.
Publicado: (2022)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
por: Hellmann, Matthew D., et al.
Publicado: (2018)

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
por: Rocco, Danilo, et al.
Publicado: (2020)

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011)

Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?
por: Kim, Yoo Na, et al.
Publicado: (2012)

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Establishment of a prospective multicenter cohort for advanced non‐small cell lung cancer in China (CAPTRA‐Lung study)
por: Xu, Yan, et al.
Publicado: (2018)

Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
por: Adderley, H., et al.
Publicado: (2020)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
por: Kataoka, Shunichi, et al.
Publicado: (2022)

Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy
por: Xiao, Mingshu, et al.
Publicado: (2022)

Potential role of immunotherapy in advanced non-small-cell lung cancer
por: de Mello, Ramon Andrade, et al.
Publicado: (2016)

Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer
por: Li, Xinpeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bi330pe1qnl8qn46nci0u1bmce